MLL1-Induced Oncogenic Reprogramming Drives EZH2 Inhibitor Resistance

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-159
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

In Vivo Reprogramming Drives Kras-Induced Cancer Development

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2018English

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells

Cancer Research
Cancer ResearchOncology
2016English

Mutant KRAS Copy-Number Gain Drives Metabolic Reprogramming

Cancer Discovery
Oncology
2016English

Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

Rare Cell Variability and Drug-Induced Reprogramming as a Mode of Cancer Drug Resistance

Nature
Multidisciplinary
2017English

Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2019English

The Targetable Kinase PIM1 Drives ALK Inhibitor Resistance in High-Risk Neuroblastoma Independent of MYCN Status

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

EZH2 Promotes Cisplatin Resistance by Reducing Cellular Platinum Accumulation

Cancer Science
Cancer ResearchMedicineOncology
2018English

TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy